)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Candel Therapeutics
Candel Therapeutics (CADL) investor relations material
Candel Therapeutics Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary12 Nov, 2026
Executive summary
Phase 3 prostate trial met its primary DFS endpoint (HR 0.70, p=0.0155); updated data showed a 41% reduction in recurrence or prostate cancer-specific death risk at median 58-month follow-up.
Aglატimagene prostate BLA submission is planned for mid-2027, subject to ongoing FDA dialogue and assay refinement.
Three SITC posters highlighted aglatimagene immune biomarker findings and linoserpaturev survival data.
Financial highlights
Q3 2026 operating expenses were $23.0M vs. $13.2M YoY; net loss was $21.9M vs. $11.3M.
Q3 R&D was $15.6M vs. $8.5M, reflecting higher clinical, manufacturing and regulatory costs, headcount and stock compensation.
Q3 G&A was $7.4M vs. $4.7M, mainly due to higher employee-related and commercial-readiness costs.
9M 2026 operating expenses were $66.0M vs. $32.5M; net loss was $69.6M vs. $8.7M.
9M operating cash use was $58.3M; financing cash inflow was $142.6M, lifting cash, cash equivalents and restricted cash to $203.5M.
Outlook and guidance
Cash and cash equivalents of $203.1M at September 30, 2026, are expected to fund the current operating plan into Q2 2028.
R&D and G&A costs are expected to rise as clinical programs advance, manufacturing capabilities develop and commercial-readiness work continues.
Additional capital will be required for aglatimagene commercialization, the NSCLC Phase 3 trial and further linoserpaturev development; potential sources include equity, debt, collaborations or licensing.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Candel Therapeutics
- Prostate Phase III success, systemic immune evidence and a Phase III NSCLC program anchor the pipeline.CADL
Stifel 2026 Healthcare Conference 2026 - Aglatimagen nears BLA filing after pivotal prostate cancer trial success; key data updates due in 2026.CADL12th Annual Cantor Fitzgerald Global Healthcare Conference
- Aglatimagene nears BLA submission after positive phase III data, with targeted launch planning underway.CADLH.C. Wainwright 28th Annual Global Investment Conference
- Net loss rose on higher R&D and commercial costs; cash supports operations into Q1 2028.CADLQ2 2026
- Aglatimagene shows strong efficacy in prostate cancer, with major regulatory and commercial momentum.CADLCanaccord Genuity's 46th Annual Growth Conference
- Aglatimagene and linoserpaturev show strong efficacy and safety in late-stage oncology trials.CADLCorporate presentation
- All director nominees and the auditor appointment were approved by stockholders.CADLAGM 2026
- Lead viral immunotherapies deliver strong efficacy in solid tumors, with pivotal trials and filings ahead.CADLJefferies Global Healthcare Conference 2026
- Late-stage immunotherapy programs advance toward commercialization and regulatory milestones.CADLR&D Day 2025
Next Candel Therapeutics earnings date
Jefferies Global Healthcare Conference18 Nov, 2026
Candel Therapeutics
Next Candel Therapeutics earnings date
Jefferies Global Healthcare Conference18 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing viral immunotherapies for cancer treatment. The company’s approach involves using genetically modified viruses to induce immunogenic cell death in cancer cells, which unmask tumor antigens within an activated microenvironment. This process triggers a systemic and durable immune response against tumors, acting as an in situ vaccination. Candel’s therapies are designed to potentially improve survival rates and maintain the quality of life for patients across various stages of cancer. The company is headquartered in Needham, Massachusetts, and its shares are listed on NASDAQ.